ClinicalTrials.gg
CompletedNCT02625259Updated Jan 8, 2018Results posted

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

A Phase 1 interventional study of TAK-117 and Lansoprazole in Neoplasm, Advanced or Metastatic, sponsored by Millennium Pharmaceuticals, Inc.. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-08.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the relative bioavailability of a new tablet formulation of TAK-117 (new clinical trial material [NTM]) compared to the TAK-117 Process B capsules (current clinical trial material [CTM]) (Part 1), to assess the effects of food on the oral bioavailability and pharmacokinetics (PK) of TAK-117 (Part 2), and to assess the effects of gastric pH-modifying agent on the PK of TAK-117 in healthy participants (Part 3).

Read the detailed description

The drug being tested in this study is called TAK-117. TAK-117 is being tested to treat people who have advanced solid tumors. This study will look at the PK and relative bioavailability of new tablet formulation of TAK-117 as compare to current capsule formulation in Part 1. In Part 2 and Part 3, interaction of TAK-117 with food and a gastric pH modifying agent will be evaluated respectively in healthy participants, and will commence only after the completion of Part 1.

The study will enroll approximately 54 participants. In Part 1, participants will be randomly assigned (by chance, like flipping a coin) to 1 of the 2 crossover sequences:

  • Sequence A: TAK-117 capsules (9*100 mg) first then TAK-117 tablets (3*300 mg)
  • Sequence B: TAK-117 tablets (3*300 mg) first then TAK-117 capsules (9*100 mg)

Part 2 and Part 3 will be evaluated only on the new tablet formulation of TAK-117 at the dose determined in Part 1. In Part 2, participants will be randomly assigned to receive a single dose of TAK-117 in the fasted state followed by TAK-117 with standard high-fat breakfast in Sequence A or vice-versa in Sequence B. In Part 3, participants will receive a single dose of TAK-117 on Day 1 followed by lansoprazole 30 mg on Day 10 for 6 days and then second dose of TAK-117 on Day 15. Blood samples will be collected at predose and up to 72 hours postdose at prespecified time points on Days 1 and 15. Urine samples will be collected predose, 0 to 12 hours, and 12 to 24 hours postdose in Part 1 only.

This single center trial will be conducted in the United States. The overall time to participate in this study is approximately 45 days. Participants will make 2 visits to the clinic in each part, during which they will remain confined to the clinic for a 4 to 10 day period for drug dosing and other study procedures. Participants will also complete a final visit 30 to 33 days after their last dose of study drug for a follow-up assessment (Day 45).

02

Conditions studied

  • Neoplasm, Advanced or Metastatic

Keywords

  • Drug therapy
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 54 is close to the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is aged 18 to 45 years inclusive, at the time of consent.
  2. Is healthy adult male or female.
  3. Weighs greater than or equal to (>=) 45 kilogram (kg) (female) or >=55 kg (male), and (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m\^2), inclusive, at screening.
  4. Suitable venous access for the study-required blood sampling, including PK sampling.
  5. Has provided the voluntary written consent.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormality at screening or medical history of cardiac, hepatic, renal, respiratory, gastrointestinal (GI), endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
  2. Manifestations of malabsorption due to prior GI surgery, GI disease, or for an unknown other reason that may alter the PK of TAK-117 or lansoprazole.
  3. less than or equal to (\<=) 90 milliliter per minute (mL/min) based either on Cockroft-Gault estimate or based on a 12- or 24-hour urine collection during screening.
  4. Known intolerance to TAK-117 or lansoprazole, or any of the of either drug.
  5. A positive test result for (HIV), hepatitis A antibody (HAVAb), surface antigen (HBsAg), hepatitis B core (HBc) antibody Anti-HBc (IgM), or antibody (HCVAb) tests at screening, or serological reactions for syphilis during screening.
  6. Has Lactose intolerance (only for Part 2).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Part 1: TAK-117 9*100 mg + TAK-117 3*300 mg

    TAK-117900 milligram (mg), capsules, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, tablets, orally, once on Day 15.

    Drug: TAK-117

  • Experimental
    Part 1: TAK-117 3*300 mg + TAK-117 9*100 mg

    TAK-117 900 mg tablets, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, capsules, orally, once on Day 15.

    Drug: TAK-117

  • Experimental
    Part 2: TAK-117 Fasted + TAK-117 Fed

    TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 15.

    Drug: TAK-117

  • Experimental
    Part 2: TAK-117 Fed + TAK-117 Fasted

    TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 15.

    Drug: TAK-117

  • Experimental
    Part 3: TAK-117 + Lansoprazole

    TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 1, followed by lansoprazole 30 mg, tablets or capsules, once daily from Day 10 to Day 15, followed by TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 15.

    Drug: Lansoprazole · Drug: TAK-117

Interventions

  • TAK-117 capsules

  • DrugLansoprazole

    Lansoprazole capsules

  • TAK-117 tablets

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for TAK-117

    Time frame: Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose

  2. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117

    Time frame: Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose

  3. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117

    Time frame: Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose

  4. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117

    Time frame: Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose

Secondary outcomes

  1. Part 1: Renal Clearance (CLr) of TAK-117

    Time frame: Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose

07

Results

Posted Jan 8, 2018

Participant flow

Participants took part in the study at 1 investigative site in the United States from 08 January 2016 to 22 July 2016.

First Intervention (Day 1)
Participant flow — First Intervention (Day 1)
MilestonePart-1: TAK-117 900 mg Capsules + TAK-117 900 mg TabletsPart-1: TAK-117 900 mg Tablets + TAK-117 900 mg CapsulesPart-2: TAK-117 600 mg Fasted + TAK-117 600 mg FedPart-2: TAK-117 600 mg Fed + TAK-117 600 mg FastedPart-3: TAK-117 900 mg + Lansoprazole 30 mg
Started11981016
Completed987916
Not completed21110
Withdrew: Other00100
Withdrew: Adverse event21000
Withdrew: Withdrawal by subject00010
Washout (Day 2 to Day 14)
Participant flow — Washout (Day 2 to Day 14)
MilestonePart-1: TAK-117 900 mg Capsules + TAK-117 900 mg TabletsPart-1: TAK-117 900 mg Tablets + TAK-117 900 mg CapsulesPart-2: TAK-117 600 mg Fasted + TAK-117 600 mg FedPart-2: TAK-117 600 mg Fed + TAK-117 600 mg FastedPart-3: TAK-117 900 mg + Lansoprazole 30 mg
Started98790
Completed98790
Not completed00000
Second Intervention (Day 15)
Participant flow — Second Intervention (Day 15)
MilestonePart-1: TAK-117 900 mg Capsules + TAK-117 900 mg TabletsPart-1: TAK-117 900 mg Tablets + TAK-117 900 mg CapsulesPart-2: TAK-117 600 mg Fasted + TAK-117 600 mg FedPart-2: TAK-117 600 mg Fed + TAK-117 600 mg FastedPart-3: TAK-117 900 mg + Lansoprazole 30 mg
Started98790
Completed98790
Not completed00000

Outcome measures

PrimaryCmax: Maximum Observed Plasma Concentration for TAK-117
Time frame:
Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for TAK-117
nanogram per milliliter (ng/mL)Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules)Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets)Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets)Part-2: TAK-117 600 mg Fed (2*300 mg Tablets)Part-3: TAK-117 900 mg (3*300 mg Tablets)Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg
Cmax: Maximum Observed Plasma Concentration for TAK-1174632.992 ± 716225.347 ± 536455.111 ± 487847.591 ± 245859.156 ± 58190.172 ± 144
Statistical analysis
  • Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules) vs Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets) · Geometric mean ratio: 1.36 · 90% CI 1.00 to 1.83
  • Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets) vs Part-2: TAK-117 600 mg Fed (2*300 mg Tablets) · Geometric mean ratio: 1.20 · 90% CI 0.86 to 1.67
  • Part-3: TAK-117 900 mg (3*300 mg Tablets) vs Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg · Geometric mean ratio: 0.03 · 90% CI 0.02 to 0.07
PrimaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117
Time frame:
Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117
hoursPart-1: TAK-117 900 mg Capsules (9*100 mg Capsules)Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets)Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets)Part-2: TAK-117 600 mg Fed (2*300 mg Tablets)Part-3: TAK-117 900 mg (3*300 mg Tablets)Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-1172.067 (1.00 to 6.00)3.000 (0.500 to 6.00)3.000 (2.00 to 6.07)6.033 (4.00 to 8.03)3.000 (1.00 to 6.00)3.517 (1.00 to 6.00)
PrimaryAUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117
Time frame:
Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117
nanogram*hour per milliliter (ng*hr/mL)Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules)Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets)Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets)Part-2: TAK-117 600 mg Fed (2*300 mg Tablets)Part-3: TAK-117 900 mg (3*300 mg Tablets)Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-11745727.280 ± 9466015.952 ± 9171442.968 ± 67127143.511 ± 3963165.064 ± 911018.650 ± 129
Statistical analysis
  • Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules) vs Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets) · Geometric mean ratio: 1.47 · 90% CI 0.98 to 2.18
  • Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets) vs Part-2: TAK-117 600 mg Fed (2*300 mg Tablets) · Geometric mean ratio: 1.76 · 90% CI 1.11 to 2.78
  • Part-3: TAK-117 900 mg (3*300 mg Tablets) vs Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg · Geometric mean ratio: 0.02 · 90% CI 0.01 to 0.04
PrimaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117
Time frame:
Part 1 and 2: Day 1 or 15 pre-dose and at multiple time points (up to 72 hours) post-dose; Part 3: Day 1 (TAK-117) and Day 15 (TAK-117 + Lansoprazole) pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Geometric mean · ng*hr/mL
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117
ng*hr/mLPart-1: TAK-117 900 mg Capsules (9*100 mg Capsules)Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets)Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets)Part-2: TAK-117 600 mg Fed (2*300 mg Tablets)Part-3: TAK-117 900 mg (3*300 mg Tablets)Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-11764165.340 ± 7796293.083 ± 7781595.634 ± 61128336.896 ± 3985782.122 ± 856547.254 ± 66
Statistical analysis
  • Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules) vs Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets) · Geometric mean ratio: 1.53 · 90% CI 0.93 to 2.51
  • Part-2: TAK-117 600 mg Fasted (2*300 mg Tablets) vs Part-2: TAK-117 600 mg Fed (2*300 mg Tablets) · Geometric mean ratio: 1.50 · 90% CI 1.00 to 2.25
  • Part-3: TAK-117 900 mg (3*300 mg Tablets) vs Part-3: TAK-117 900 mg (3*300 mg Tablets) + Lansoprazole 30 mg · Geometric mean ratio: 0.08 · 90% CI 0.03 to 0.18
SecondaryPart 1: Renal Clearance (CLr) of TAK-117
Time frame:
Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose
Reported as:
Mean · liter per hour (L/hr)
Part 1: Renal Clearance (CLr) of TAK-117
liter per hour (L/hr)Part-1: TAK-117 900 mg Capsules (9*100 mg Capsules)Part-1: TAK-117 900 mg Tablets (3*300 mg Tablets)
Part 1: Renal Clearance (CLr) of TAK-1170.314 ± 0.11790.311 ± 0.1304

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days (Day 46) after the last dose of study drug. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part-1: TAK-117 900 mg Capsules—0/19 (0%)3/19 (15.8%)
Part-1: TAK-117 900 mg Tablets—0/18 (0%)5/18 (27.8%)
Part-2: TAK-117 600 mg Fasted—0/17 (0%)8/17 (47.1%)
Part-2: TAK-117 600 mg Fed—0/17 (0%)4/17 (23.5%)
Part-3: TAK-117 900 mg—0/16 (0%)6/16 (37.5%)
Part-3: Lansoprazole 30 mg—0/16 (0%)1/16 (6.3%)
Part 3: Lansoprazole 30 mg + TAK-117 900 mg—0/16 (0%)1/16 (6.3%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPart-1: TAK-117 900 mg CapsulesPart-1: TAK-117 900 mg TabletsPart-2: TAK-117 600 mg FastedPart-2: TAK-117 600 mg FedPart-3: TAK-117 900 mgPart-3: Lansoprazole 30 mgPart 3: Lansoprazole 30 mg + TAK-117 900 mg
NauseaGastrointestinal disorders3/193/187/174/175/160/160/16
VomitingGastrointestinal disorders3/192/181/171/170/160/160/16
HeadacheNervous system disorders1/190/182/170/172/161/160/16
DiarrhoeaGastrointestinal disorders0/190/181/170/171/160/160/16
Abdominal painGastrointestinal disorders0/190/180/170/171/160/160/16
Decreased appetiteMetabolism and nutrition disorders1/190/180/170/171/160/160/16
DizzinessNervous system disorders1/190/181/170/171/160/160/16
ParaesthesiaNervous system disorders0/190/180/170/170/160/161/16
CoughRespiratory, thoracic and mediastinal disorders0/190/180/170/170/161/160/16
Dry throatRespiratory, thoracic and mediastinal disorders0/190/180/170/171/160/160/16

Baseline characteristics

Safety analysis population included all the participants who received at least 1 dose of study drug.

Age, Customized
Age, Customized(participants)Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg TabletsPart-1: TAK-117 900 mg Tablets + TAK-117 900 mg CapsulesPart-2: TAK-117 600 mg Fasted + TAK-117 600 mg FedPart-2: TAK-117 600 mg Fed + TAK-117 600 mg FastedPart-3: TAK-117 900 mg + Lansoprazole 30 mgTotal
18-45 years11 ± 7.639 ± 7.798 ± 7.1510 ± 6.1316 ± 6.8854
Sex: Female, Male
Sex: Female, Male(Participants)Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg TabletsPart-1: TAK-117 900 mg Tablets + TAK-117 900 mg CapsulesPart-2: TAK-117 600 mg Fasted + TAK-117 600 mg FedPart-2: TAK-117 600 mg Fed + TAK-117 600 mg FastedPart-3: TAK-117 900 mg + Lansoprazole 30 mgTotal
Female87410938
Male3240716
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg TabletsPart-1: TAK-117 900 mg Tablets + TAK-117 900 mg CapsulesPart-2: TAK-117 600 mg Fasted + TAK-117 600 mg FedPart-2: TAK-117 600 mg Fed + TAK-117 600 mg FastedPart-3: TAK-117 900 mg + Lansoprazole 30 mgTotal
Hispanic or Latino6444624
Not Hispanic or Latino55461030
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg TabletsPart-1: TAK-117 900 mg Tablets + TAK-117 900 mg CapsulesPart-2: TAK-117 600 mg Fasted + TAK-117 600 mg FedPart-2: TAK-117 600 mg Fed + TAK-117 600 mg FastedPart-3: TAK-117 900 mg + Lansoprazole 30 mgTotal
American Indian or Alaska Native010012
Asian101002
Native Hawaiian or Other Pacific Islander000000
Black or African American2333819
White8547529
More than one race000022
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Part-1: TAK-117 900 mg Capsules + TAK-117 900 mg TabletsPart-1: TAK-117 900 mg Tablets + TAK-117 900 mg CapsulesPart-2: TAK-117 600 mg Fasted + TAK-117 600 mg FedPart-2: TAK-117 600 mg Fed + TAK-117 600 mg FastedPart-3: TAK-117 900 mg + Lansoprazole 30 mgTotal
United States1198101654
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in May 2016, 4 months.

Results were first posted in Jan 2018, 1 year 7 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 4 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2015
First posted
Dec 9, 2015
StartActual
Jan 8, 2016
Primary completionActual
May 16, 2016
CompletionActual
Jul 22, 2016
Results first posted
Jan 8, 2018
Last update
Jan 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02625259
Responsible party
Sponsor
First posted
Dec 9, 2015
Start date
Jan 8, 2016
Primary completion
May 16, 2016
Completion
Jul 22, 2016
Results posted
Jan 8, 2018
Last update
Jan 8, 2018

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serabelisib

Start the discussion